AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01183689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small Behavior Changes
Description: The Self-Regulation Plus Small Behavior Changes Intervention will focus on making small changes in diet and physical activity on a daily basis to prevent weight gain.~Diet: The dietary approach used in this group is to identify small changes in what and how much participants eat each day. The general concept is that these are small, manageable changes that will produce small reductions in overall intake and can easily be made on a daily basis and maintained over time.~Exercise: At the start of the program, participants will be given a pedometer and asked to record their current or baseline number of steps. They will then be given the goal of increasing their daily steps by 2000 steps per day over this baseline level.
Study NCT01183689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Large Behavior Changes
Description: The focus of this intervention group will be on periodically making large changes in diet and physical activity, with the goal of losing 5-10 pounds to buffer against the weight gain that often occurs during young adulthood.~Diet: Individuals with a BMI of 21-24.9 kg/m2 will be encouraged to lose 5 pounds; those with a BMI of 25-30 kg/m2 will be encouraged to lose 10 pounds.~Exercise: The Large Changes group will be instructed to gradually increase their minutes of physical activity until achieving 250 minutes per week (5 days/week with 50 minutes per day) using activities similar in intensity to brisk walking.
Study NCT01414803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid modification
Description: rosuvastatin 10 mg/fenofibrate 160 mg per day
Study NCT01414803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipid modification
Description: rosuvastatin 10 mg per day
Study NCT03247647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention
Description: Participants will complete a personal values task immediately before viewing feedback from eCheckUpToGo.
Study NCT03247647 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Intervention
Description: Participants will write about the food they have eaten in the last 48 hours.
Study NCT02649582 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccine plus temozolomide chemotherapy
Description: When eligible after total or subtotal resection (as assessed by neurosurgeon and post-operative brain MRI):~1. Leukocyte apheresis (before chemoradiation): for DC vaccine production~2. Chemoradiation (standard treatment: initiated as soon as the patient's hematological blood values are adequate after apheresis): 2 Gy once daily 5 days/week for 6 weeks with 75 mg/m² temozolomide daily from the first until the last day of radiotherapy (no longer than 49 days in total)~3. Induction immunotherapy: intradermal vaccination with autologous WT1 mRNA-loaded DCs weekly (+/-1 day) for 3 weeks, starting ≥ 1 week after radiotherapy~4. Chemo-immunotherapy: 150-200 mg/m²/d temozolomide days 1-5 every 28 days +/- 2 days (max. 12 months) starting ≥3 days after the third vaccine of the induction immunotherapy + DC vaccination on day 21±3 days of every 28-day cycle
Study NCT02173769 — intervention group
Intervention type: DRUG
Intervention: Spiriva® Respimat®
Description: Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Microgramm plus Striverdi® Respimat®
Study NCT02173769 — intervention group
Intervention type: DRUG
Intervention: Striverdi® Respimat®
Description: Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Microgramm plus Striverdi® Respimat®
Study NCT01361230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sedation Trial Monitor is the name of the device used.
Description: This is a pilot unblinded randomised controlled trial comparing sedation management using responsiveness (new intervention) with usual care (control group).
Study NCT00181168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Euthyroid Group
Description: Euthyroid Group: Received rhTSH to prepare for radioiodine therapy.
Study NCT01775501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200mg/m2 administered IV on Days 1 and 15 of a 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT01775501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 5-FU continuous infusion: 2400mg/m2 total (1200mg/m2/d on day 1 and 2) to start on Day 1 and Day 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT01775501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2 IV on Days 1 and 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT01775501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400mg po BID continuously for a 2 week lead-in phase and then Days 1-28 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT02151864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Description: LDE225 will be administered orally, on a continuous once daily dosing schedule at a dose determined by the cohort the patient is enrolled in until progression or unacceptable toxicity develops
Study NCT03459079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanifibranor
Description: The film-coated tablet contains 400 mg of the active ingredient lanifibranor (IVA337) for an immediate release formulation. Participants receive 800mg/ day
Study NCT03459079 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablets with a core containing 900 mg of a physical mixture of lactose monohydrate, microcrystalline cellulose, pre-gelatinized starch and magnesium stearate serve as placebo.
Study NCT00631514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
Study NCT00631514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
Study NCT00631514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: piroxicam
Description: acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
Study NCT00879736 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: THT PACE Training
Description: Patient training
Study NCT00879736 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03016728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Participants will receive a 12-week home-based physical activity program that has been individualized using their baseline assessment results. The program will be comprised of aerobic training (2 days/week) and resistance training (2 days/week). The aerobic training will be performed unsupervised. The resistance training will be performed under the supervision of a study team member (who will visit participants homes) for the first 6 weeks to ensure proper form and safety.
Study NCT01195766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab in addition with ESHAP therapy
Study NCT02437045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem is a carbapenem anti-bacterial used for the treatment of serious infections in patients.
Study NCT02437045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam combination product
Description: Piperacillin-tazobactam is used for the treatment of patients with systemic and/or local bacterial infections.
Study NCT05690139 — intervention group
Intervention type: PROCEDURE
Intervention: Pre-operative LSG patients
Description: Baseline
Study NCT05690139 — intervention group
Intervention type: PROCEDURE
Intervention: Post-operative patients 1st month
Description: 1 month after surgery
Study NCT05690139 — intervention group
Intervention type: PROCEDURE
Intervention: Post-operative patients 3rd month
Description: 3 months after surgery
Study NCT05690139 — intervention group
Intervention type: PROCEDURE
Intervention: Post-operative patients 6th month
Description: 6 months after surgery
Study NCT04642027 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional sEBRT
Description: A total dose of70 Gy in 35 daily fractions of 2 Gy during 7 weeks
Study NCT04642027 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated sEBRT
Description: A total dose of 60 Gy in 20 daily fractions of 3 Gy during 4 weeks
Study NCT02759614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle and Erlotinib orally once daily at 150mg/day
Study NCT02759614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150mg, orally once a day
Study NCT02759614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib 150mg, orally once a day
Study NCT03938233 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A low-cost DSME program and scalable delivery model for roll-out within the Thai primary care system
Description: The intervention will be based on behaviour-change and social support theories, delivered in monthly group meetings by lay health workers or nurses, and aided by a suite of short films to introduce key topics and stimulate discussion.
Study NCT03117751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given orally (PO).
Study NCT03117751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given intravenously (IV).
Study NCT03117751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV.
Study NCT03117751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV or intramuscularly (IM) .
Study NCT03117751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase®
Description: To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV or intramuscularly (IM).
Study NCT02731573 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open heart surgery
Description: Subject will undergo open heart surgery according to standard of care
Study NCT00618982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: The initial dose of sorafenib will be 400 mg bid administered orally, on a continuous basis. A treatment cycle is considered to be 28 days. Intrapatient dose escalation will occur according to the following schedule, providing no grade 3 or 4 toxicities are observed (except for alopecia, nausea and vomiting); Day 1-28 400 mg bid, Day 29-56 600 mg bid, Day 57 onwards 800 mg bid. Subjects will continue on treatment until progression, unacceptable toxicity, subject withdraws consent or the decision is taken to stop the study following the analysis of response rates.
Study NCT04340323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training (PFMT)
Description: The method of first choice in SUI treatment according to the International Continence Society (ICS) is training of the pelvic floor muscles. Pelvic floor muscle training (PFMT) is a method based on scientific evidence, defined by the ICS as repeated selective voluntary contraction and relaxation of specific pelvic floor muscles. It is important to train the strength and endurance of the pelvic floor muscles but also their relaxation (Abrams, 2018; Arnold, 2014; Bo, 2013).
Study NCT04340323 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Muscle Training (PFMT)
Description: The method of first choice in SUI treatment according to the International Continence Society (ICS) is training of the pelvic floor muscles. Pelvic floor muscle training (PFMT) is a method based on scientific evidence, defined by the ICS as repeated selective voluntary contraction and relaxation of specific pelvic floor muscles. It is important to train the strength and endurance of the pelvic floor muscles but also their relaxation (Abrams, 2018; Arnold, 2014; Bo, 2013).
Study NCT03573726 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Closed diurnal indwelling catheter (CDIC)
Description: Each participant underwent an evaluation during standard of care CIC use vs evaluations during use of the study intervention (CDIC).
Study NCT01895283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-intensity training
Description: Training at 70% of VO2max, for 1/2 hour, three times weekly, for 10 weeks, on a bike ergometer.
Study NCT03078426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany). Acquisitions will be obtained in the axial plane using a 12-channel thorax/spine coil. Investigators will use previously published sequence parameters for each MRI sequence. PETRA will be acquired under free-breathing with respiratory gating at functional respiratory capacity.
Study NCT03078426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic HRCT (standard reference)
Description: It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.
Study NCT01676181 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adenotonsillectomy
Description: Total removal of tonsils and adenoid tissue with cold-steel
Study NCT01676181 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adenotonsillotomy
Description: Partial removal of tonsils with coblation and total removal of adenoids with cold steel
Study NCT01991054 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin D3
Study NCT01991054 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3
Study NCT01583153 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hospital Inpatient Rehabilitation
Description: Those allocated to HI will be admitted to the adjacent rehabilitation hospital, Braeside Rehabilitation Hospital, for 10 days. As per the private sector, HI participants will receive twice-daily supervised physiotherapy comprising 1-1.5 hr class-based exercises and 1-1.5 hr one-to-one therapy. Prior to discharge, participants will be familiarised with the home programme as described in second arm. All participants will be required to complete a diary detailing programme adherence, healthcare utilisation, and social costs relating to carer-burden. Participants will attend the group-based sessions as per HO below for monitoring and progression of programme. An additional FIM outcome measure will be taken for this arm on admission and discharge from the inpatient rehab unit.
Study NCT01583153 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid Home Programme (HO)
Description: The HO will be based on what is standard care in the local health district and guidelines for exercise in the elderly and those with osteoarthritis. Approximately 2 weeks post-surgery, participants allocated to the HO will attend 1 group-based exercise session in the Physiotherapy Department (Fairfield Hospital) where the home programme will be rehearsed and exercises individualised as required due to co-morbidities. The programme comprises general aerobic components as well as general functional and muscle-specific exercises focused on restoring knee mobility, lower limb strength, and normal neuromuscular co-ordination and gait patterns. Participants will be able to return for 2-3 sessions over the 6-week period.
Study NCT02935933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivicaine
Description: Paravertebral block
Study NCT03117751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV.
Study NCT02935933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Study NCT02935933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Study NCT04181684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Procedure: LITT
Description: This procedure is done under MRI guidance and employs low-powered thermal energy to achieve tumor ablation through coagulation.
Study NCT04181684 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypo-Fractionated Radiation Therapy
Description: Treatments will be delivered once daily on consecutive treatment days (typically 5 fractions per week). Radiation therapy simulation is to be performed within 10 days of the LITT procedure.
Study NCT02337751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVP-1012 1mg
Description: TVP-1012 1mg Tablets
Study NCT00369473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 108
Description: 125 mg via SC (subcutaneous) injection every 4 weeks
Study NCT00369473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 108
Description: 250 mg via SC (subcutaneous) injection every 4 weeks
Study NCT02793076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bollywood Dance
Description: 8 week Bollywood Dance Program
Study NCT01389427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel dose 15 mg and R-CHOP
Description: Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Study NCT01389427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel dose 15 mg and R-FC
Description: Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Study NCT01389427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel dose 15 mg and R-DHA
Description: Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Study NCT01389427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel dose 25 mg and R-CHOP
Description: Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Study NCT01389427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel dose 50 mg and R-CHOP
Description: Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Study NCT01389427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel dose 75 mg and R-CHOP
Description: Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Study NCT01389427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel dose 25 mg and R-FC
Description: Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Study NCT01389427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel dose 50 mg and R-FC
Description: Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Study NCT01389427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel dose 75 mg and R-FC
Description: Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Study NCT01389427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel dose 25 mg and R-DHA
Description: Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Study NCT01389427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel dose 50 mg and R-DHA
Description: Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Study NCT01389427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel 75 mg and R-DHA
Description: Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Study NCT00832182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Insulin aspart at breakfast, lunch and dinner time. Neutral protamine Hagedorn insulin at breakfast, lunch, dinner and bedtime. Injections were optional but at least one injection per day
Study NCT00832182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin NPH
Description: Insulin aspart at breakfast, lunch and dinner time. Neutral protamine Hagedorn insulin at breakfast, lunch, dinner and bedtime. Injections were optional but at least one injection per day
Study NCT05569031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: patients with tramadol abuse will use venlafaxine for 10 days.